Free Biopharma Daily Stock Updates - 09/17/21

$XBI $133 +1%

---

Covid Updates

$PFE -1% FDA ADVISORY COMMITTEE VOTES UNANIMOUSLY IN FAVOR OF COMIRNATY® BOOSTER FOR EMERGENCY USE IN PEOPLE 65 AND OLDER AND CERTAIN HIGH-RISK POPULATIONS. source

Pipeline Updates

$EXEL +1% Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer. source

$DCPH +4% Deciphera Announces Positive CHMP Opinion for QINLOCK® for the Treatment of Fourth-line Gastrointestinal Stromal Tumor. source

$AZN -2% Imfinzi combined with novel immunotherapies improved clinical outcomes for patients with unresectable, Stage III non-small cell lung cancer. source

$GLPG +1% GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS. source

$SESN -2% Withdrew MAA and plans to meet with FDA in Q4 2021 to decide next steps. source

$GRTX +3% Gritstone Announces Dosing of First Solid Tumor Patient with Optimized SLATE “Off-the-Shelf” Mutant KRAS-directed Neoantigen Immunotherapy in Phase 2 Clinical Trial. source

$PTGX -62% Protagonist Therapeutics Reports FDA Clinical Hold on Rusfertide Clinical Development Program. source

$EYPT +9% EyePoint Pharmaceuticals to Present Data at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting. source

$CLNN +5% Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021. Ph 2 RESCUE-PD to initiate H2 2021. source

Finance & Business Updates

$IPSC -15% Century Therapeutics Announces Its Addition to the Russell 2000® Index. source

$AVTX -3% Avalo Therapeutics, Inc. Announces Closing of a $31.5 Million Public Offering of Common Stock, Including Proceeds from Exercise of Option to Purchase Additional Shares. source

---

Posted by DV